Rheumatology Associates PC — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$1,562	1
2023	Research	$7,500	1
2022	Research	$2,876	3
2021	Research	$11,267	3
2020	Research	$149,803	6
2019	Research	$128,287	9

Breakdown

Who paid Research payments · program years 2019–2024

Novartis Pharmaceuticals Corporation $268,380 12 payments
Janssen Research & Development, LLC $11,328 4 payments
Gilead Sciences, Inc. $9,260 2 payments
Pfizer Inc. $6,973 4 payments
Eli Lilly and Company $5,355 1 payment

Studies the money was for Research payments · program years 2019–2024

A Randomized Double Blind Placebo Controlled Phase III Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 16 Weeks and to Assess the Long Term Efficacy Safety and Tolerability Up to 52 Weeks in Patients With $227,103 3 payments
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Multicenter Study of Intravenous Secukinumab to Compare Efficacy at 16 Weeks With Placebo and to Assess Safety and Tolerability Up to 52 Weeks in Subjects With Active Psoriatic Arth $26,074 3 payments
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Multicenter Study of Intravenous Secukinumab to Compare Efficacy at 16 Weeks With Placebo and to Assess Safety and Tolerability Up to 52 Weeks in Subjects With Active Psoriatic Arthritis $10,531 1 payment
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent $7,500 1 payment
Phase III Pivotal Study 1 of Tofacitinib Cp690550 in Ankylosing Spondylitis $6,170 3 payments
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed By Long Term Evaluation of Efficacy and Safety of Ixekizumab Ly2439821 in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis $5,355 1 payment
A Phase 3, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects with Active Ankylosing Spondylitis Who Are Naive to Biologic Disease Modifying Antirheumatic Drug Therapy $4,630 1 payment
A Phase 3, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects with Active Ankylosing Spondylitis Who Have an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drug Therapy $4,630 1 payment
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Multicenter Study of Intravenous Secukinumab to Compare Efficacy at 16 Weeks With Placebo and to Assess Safety and Tolerability Up to 52 Weeks in Subjects With Active Ankylosing Spo $3,936 3 payments
Cnto1959psa3004 $1,562 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.